ArticleCancer biology & therapy2024

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway.

Minxue Gai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.